evaluating clinical research

Furberg, Bengt D.; Furberg, Curt D.

evaluating clinical research

Bengt D. Furberg () and Curt D. Furberg ()
Additional contact information
Bengt D. Furberg: Associate Professor
Curt D. Furberg: Wake Forest University School of MedicineMedical Center Boulevard, Division of Public Health Sciences

in Springer Books from Springer

Date: 2007
ISBN: 978-0-387-72899-5
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Chapters in this book:

Ch Chapter 1 What is the purpose of this book?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 10 Why is blinding/masking so important?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 11 How is symptomatic improvement measured?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 12 Is it really possible to assess quality of life?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 13 What is the value of biologic markers in drug evaluation?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 14 How are adverse drug reactions measured?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 15 How representative are study subjects in clinical trials?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 16 What happened to the study subjects who disappeared from the analysis?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 17 How reliable are active-control trials?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 18 How informative are composite outcomes?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 19 Do changes in biologic markers predict clinical benefit?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 2 Why is benefit-to-harm balance essential to treatment decisions?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 20 How trustworthy are the authors?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 21 Does publication in a reputable scientific journal guarantee quality?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 22 Is it necessary to be a biostatistician to interpret scientific data?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 23 Are all drugs of a class interchangeable?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 24 How much confidence can be placed on economic analysis?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 25 How should I handle the massive flow of information?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 26 How well is research translated into clinical care?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 3 What are the strengths of randomized controlled clinical trials?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 4 What are the weaknesses of randomized controlled clinical trials?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 5 Do meta-analyses provide the ultimate truth?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 6 What are the strengths of observational studies?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 7 What are the weaknesses of observational studies?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 8 Were the scientific questions stated in advance?: Bengt D. Furberg and Curt D. Furberg
Ch Chapter 9 Were the treatment groups comparable initially?: Bengt D. Furberg and Curt D. Furberg

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprbok:978-0-387-72899-5

Ordering information: This item can be ordered from
http://www.springer.com/9780387728995

DOI: 10.1007/978-0-387-72899-5

Access Statistics for this book

More books in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().